Page 84 - Human Use News Today

A bill in Tennessee with the intention of protecting consumers was set to be discussed in committees last ...

Twenty of the common cough and cold medicines, including Day and Night Nurse capsules, have been urgently withdrawn from the market on the order of the drug regulators because of concerns about a “very rare” risk of anaphylaxis, a life-threatening adverse event.

Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP PDUFA date has been set for 16 August 2023 following the New Drug Application

Investegate announcements from Ipsen Pharma, Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP

/PRNewswire/ -- The European Medicines Agency has just granted an extension of the indication for the marketing authorisation for WAKIX® (pitolisant), which is...

Full year product revenue of $22.2 million; commercial launches of RELYVRIO® in U.S. and ALBRIOZA™ in Canada continue to progressRegulatory review ongoing in the EUKaren Firestone, CEO and co-founder of Aureus Asset Management and prior fund manager at Fidelity Investments, appointed to the Company's Board of Direct...

Operator: Good day ladies and gentlemen. Thank you for standing by and welcome to Akebias Fourth Quarter 2022 Financial Results Conference Call.

ZTALMY® U.S. net product revenue of $2.3 million for the fourth quarter of 2022 and $2.9 million for the fiscal year ended December 31, 2022Company expects ZTALMY U.S. net product revenues of between $15 million and $17 million for the fiscal year ending December 31, 2023Second generation oral formulation developmen...

PPQ campaign to start early May 2023 (previously end of March) with results expected in Q3 2023 EMA CHMP opinion now expected in Q1 2024 (previously September 2023) Regulatory News: GenSight

The therapy becomes the first pegylated enzyme for the treatment of adult patients with Fabry disease - News - PharmaTimes